WASHINGTON, D.C. (February 1, 2005) – The Biotechnology Industry Organization (BIO) will host the third annual briefing on industrial biotechnology for securities analysts and investors on Feb. 22, 2005. The half-day briefing will emphasize progress in the growing industrial enzyme, small molecule production, nanotechnology, bioenergy and biobased materials markets. Presentations will also highlight investment opportunities in “green” technologies, such as the production of clean-burning ethanol and cleaner manufacturing using biotech.. The invitation-only event will take place from 11:00 a.m. to 4:00 p.m. at the Waldorf=Astoria Hotel in New York City.
Analysts and investors interested in attending should contact Sarah Lux at (212) 362-1200 or send an email with contact information to firstname.lastname@example.org.
Media interested in attending can register on the Web site, http://ceo.bio.org or by contacting Erin Reese at 202-962-9200 or email@example.com.
Attendees of the Third Wave 2005 briefing will learn how industrial biotechnology is rapidly transforming multiple industries, creating new value chains and producing novel solutions to economic and environmental problems.
Panel sessions will feature senior management from DuPont, Diversa, DSM, Dyadic International, Iogen, Genencor International, Novozymes and Metabolix discussing the following topics:
· Industrial Biotechnology Drug Discovery and Production;
· Industrial Enzymes for Cleaner Manufacturing and Chemical Synthesis;
· Innovative Solutions for Polymer Production; and
· New Biotech Production Methods for Ethanol Transportation Fuel.
Confirmed panel participants include Jean-Jacques Bienaimé, chairman, president and CEO of Genencor International; Steen Riisgaard, president and CEO of Novozymes; James Barber, president and CEO of Metabolix; Mark Emalfarb, CEO of Dyadic International; Jay Short, president and CEO of Diversa; Maurice Hladik, director of marketing at Iogen; John Ranieri Vice President DuPont, Colja Laane, Vice Presdient DSM, and speakers from Portfolio 21 and other green investment funds.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.